Navigation Links
Vaxgen Files 10-Q for First Quarter With SEC, Provides Future Burn Rate Guidance
Date:5/14/2008

SOUTH SAN FRANCISCO, Calif., May 14 /PRNewswire-FirstCall/ -- VaxGen, Inc. (OTC Bulletin Board: VXGN), a biopharmaceutical company, today provided guidance on its expected monthly cash expenditures following the most recent restructuring undertaken on April 9, 2008. VaxGen expects that its average monthly cash expenditures going forward are unlikely to exceed $1 million, made up of the following categories:

* Costs related to the Company's real estate and facility, estimated at

32% of monthly expenditures.

* Costs related to maintaining public company status, including

professional fees, at approximately 32% of monthly expenditures.

* Costs related to the company's six remaining permanent staff and

temporary support, at approximately 21% of monthly expenditures.

* Interest payments associated with the outstanding convertible debt at

approximately 15% of monthly expenditures.

"With the completion of the most recent reduction in force, we have concluded those significant cost-reduction measures that are under the Company's sole control," said James P. Panek, VaxGen President and CEO. "While we continue to explore every avenue to reduce costs, a further significant reduction will be a function of the resolution of our efforts to sell the manufacturing plant and assign the associated lease. We are in discussions with parties interested in the plant, but cannot at this point provide assurance that a transaction will result."

VaxGen further announced today the filing of its financial results for the quarter ending March 31, 2008 on Form 10-Q with the Securities and Exchange Commission. These results reflect a number of significant impacts consequent to the termination of the proposed merger with Raven biotechnologies as follows:

* Consistent with SFAS 144, "Accounting for the Impairment and Disposal of

Long-Lived Assets" the property and equipment related to VaxGen's

manufacturing facility have been reclassified as "assets held for sale".

This reclassification shifts $10.3 million of assets on the balance

sheet out of Property and Equipment and into Current Assets. As it

relates to the Statement of Operations depreciation is not charged

against assets held for sale, and as a consequence there will be a

significant reduction in the depreciation charge going forward.

* VaxGen's net loss of $7.5 million for the first quarter of 2008 reflects

$2.3 million of expenses associated with the terminated merger and also

reflects a non-cash charge of $1.6 million related to the increase in

value of the derivative liability associated with the Company's

convertible notes. The main reason for the increase in the derivative

liability is management's assessment that there is an increased

probability of a change of control event, as defined in the indenture

related to the notes.

* VaxGen's net cash used in operating activities of $4.9 million for the

first quarter of 2008 reflects approximately $1.8 million of cash

expended on costs related to the proposed Raven merger during the

quarter.

About VaxGen

VaxGen is a biopharmaceutical company based in South San Francisco, California. The company owns a state-of-the-art biopharmaceutical manufacturing facility with a 1,000-liter bioreactor that can be used to make cell culture or microbial biologic products. For more information, please visit the company's web site at http://www.vaxgen.com.

Note: This press release contains "forward-looking statements" within the meaning of the federal securities laws, including statements regarding the VaxGen's anticipated cash expenditures and its potential sale of assets and assignment of lease. These statements are subject to risks and uncertainties that could cause actual results and events to differ materially from those anticipated. Additional information concerning these and other risk factors is contained in VaxGen's Annual Report on Form 10-K for the year ended December 31, 2007. Readers are cautioned not to place undue reliance on these forward-looking statements that speak only as of the date of this release. VaxGen undertakes no obligation to update publicly any forward-looking statements to reflect new information, events, or circumstances after the date of this release except as required by law.

(Logo: http://www.newscom.com/cgi-bin/prnh/19991112/VAXGENLOGO)


'/>"/>
SOURCE VaxGen, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. VaxGen Sells Anthrax Vaccine Program and Related Assets and Technology to Emergent BioSolutions, Inc.
2. VaxGen and Raven Terminate Merger Agreement
3. VaxGen Issues Rebuttal to MedCap Letter
4. VaxGen Common Stock Now Quoted on OTC Bulletin Board
5. VaxGen Reports Financial Update
6. VaxGen to Present at the 10th Annual BIO CEO and Investor Conference
7. VaxGen and Raven Announce Form S4 Registration Statement Declared Effective
8. VaxGen Stockholders Overwhelmingly Approve Reverse Split Proposal
9. VaxGen Common Stock Expected to Qualify for Quotation on OTC Bulletin Board
10. VaxGen Addresses MPM Claims in Letter to Stockholders
11. VaxGen Files Last Outstanding Periodic Report With SEC
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/22/2017)... ... February 22, 2017 , ... ProMIS Neurosciences (“ProMIS” or the ... diseases, today announced it has issued a scientific white paper entitled “Results from ... series of commentaries from ProMIS’s scientific team offering insight into the Company’s product ...
(Date:2/22/2017)... Origin (Origin Agritech, LLC, a subsidiary of Origin Agritech ... Arcadia (Arcadia Biosciences, Inc., NASDAQ: RKDA), a ... productivity traits and nutritional products, today announced their collaboration to achieve ... China to the United States ... ...
(Date:2/22/2017)... and SAN DIEGO , Feb. ... "Company") (OTCQB:CELZ) announced today expansion of its translational ... cell product through establishment of laboratory facilities in ... at the San Diego BioLabs facility, a biotechnology ... Novartis, and Sanofi. In November 2016, ...
(Date:2/21/2017)... ... February 21, 2017 , ... During HIMSS 2017, ... health applications, announced a partnership with Redox, a leader in cloud-based healthcare integration ... clinical systems while keeping data secure in the cloud. , The digital health ...
Breaking Biology Technology:
(Date:2/8/2017)... 2017  Aware, Inc. (NASDAQ: AWRE ), a ... results for its quarter and year ended December 31, 2016. ... was $3.9 million compared to $6.9 million in the same ... 2016 was $0.6 million compared to $2.6 million in the ... of 2016 was $0.5 million, or $0.02 per diluted share, ...
(Date:2/7/2017)... Ind. , Feb. 7, 2017 Zimmer ... leader in musculoskeletal healthcare, will present at the LEERINK ... New York Palace Hotel on Wednesday, February 15, 2017 ... live webcast of the presentation can be accessed at ... replay following the conference via Zimmer Biomet,s Investor Relations ...
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
Breaking Biology News(10 mins):